VERICEL CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.53 USD | +0.02% |
|
-2.00% | +36.28% |
Presenter SpeechJames Austin (Analysts)Good morning, and thank you for joining us today for th...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.
Sector
Pharmaceuticals
Calendar
2024-07-30
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
48.53
USD
Average target price
55.4
USD
Spread / Average Target
+14.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +36.28% | 2.36B | |
| -1.26% | 89.46B | |
| +2.76% | 40.74B | |
| -12.32% | 33.03B | |
| +52.41% | 24.68B | |
| -17.39% | 15.12B | |
| -42.45% | 11.64B | |
| -10.48% | 11.79B | |
| +6.14% | 8.9B | |
| -7.72% | 8.22B |
- Stock Market
- Equities
- VCEL Stock
- News Vericel Corporation
- Transcript : Vericel Corporation Presents at JPMorgan 40th Annual Healthcare Conference, Jan-12-2022 07